15:42 , Jul 25, 2019 |  BC Innovations  |  Distillery Therapeutics

A tumor-targeted Bavencio conjugate with enhanced antitumor efficacy

DISEASE CATEGORY: Cancer INDICATION: Melanoma Coupling a pegylated α-MSH analog to anti-PD-1 antibodies could enhance antitumor immunity. α-MSH is the ligand for MC1R, a receptor upregulated in melanoma cells. Conjugating the α-MSH analog to the...
01:49 , Mar 22, 2019 |  BC Innovations  |  Targets & Mechanisms

Deconvoluting translation at Scripps

With three institutes now under one roof, Scripps Research has established both its own pipeline and a non-profit funding model to bring candidates through early stage clinical trials. Diverging from the philanthropy and investor-based approaches...
14:29 , Mar 19, 2019 |  BC Innovations  |  Distillery Therapeutics

New brain-penetrating RIPK2 inhibitor prodrug for GBM

DISEASE CATEGORY: Cancer INDICATION: Brain cancer Cell culture and mouse studies identified a brain-penetrating naphthoquinone-based prodrug of a RIPK2 inhibitor that could help treat glioblastoma multiforme (GBM). Screening a library of drug-like small molecules in...
04:47 , Nov 9, 2018 |  BC Innovations  |  Tools & Techniques

HitGen’s DNA for small molecules

With more than 60 partnerships under its belt, HitGen Ltd. has become a major gateway for companies to access DNA-encoded library technology -- a high efficiency form of combinatorial chemistry that upstages high throughput screening....
19:25 , Oct 11, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Cryptosporidium Cell culture and mouse studies identified two compounds that could help treat Cryptosporidium infections. Screening of 12,000 approved or investigational compounds in a C. parvum -infected human cell line identified two compounds, VB-201...
14:57 , Jun 29, 2018 |  BC Week In Review  |  Company News

AbbVie, Calibr to develop universal CAR T therapies

AbbVie Inc. (NYSE:ABBV) and the California Institute for Biomedical Research (La Jolla, Calif.) partnered to develop universal CAR T therapies using the non-profit's switchable CAR T technology to treat hematological and solid tumors. AbbVie will...
11:26 , Jun 25, 2018 |  BC Extra  |  Company News

AbbVie, Calibr to develop universal CAR T therapies

AbbVie Inc. (NYSE:ABBV) and the California Institute for Biomedical Research (La Jolla, Calif.) partnered to develop universal CAR T therapies using the non-profit's switchable CAR T technology to treat hematological and solid tumors. AbbVie will...
23:27 , May 1, 2018 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Inflammatory bowel disease (IBD) Mouse studies identified a peptide-based GLP-2R activator that could help treat IBD. Chemical synthesis and testing in a cell-based activity assay of GLP-2-based stapled peptides yielded a peptide that activated...
00:21 , Mar 22, 2018 |  BC Innovations  |  Translation in Brief

Mining marine metabolites

Bristol-Myers Squibb Co. (NYSE:BMY) is tapping Sirenas LLC’s AI platform Atlantis to discover microbiome metabolites for immuno-oncology. Atlantis applies data mining, computational modeling and machine learning technology to screen microbiome-derived metabolites against cellular and biochemical...
02:10 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...